ArticleAmerican journal of respiratory cell and molecular biology2021
The Central Role of PAI-1 in COVID-19: Thrombosis and beyond.
Article in American journal of respiratory cell and molecular biology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 31 citations in OpenAlex.
- The immunothrombosis pathway linking pulmonary disease to stroke and neurodegeneration: mechanisms and therapeutic implications.Frontiers in pharmacology · 2026Review
- Bidirectional Regulatory Roles in the Immune Modulation, Organ Dysfunction, and Therapy of Sepsis.International journal of nanomedicine · 2025Review
- The fatal contribution of serine protease-related genetic variants to COVID-19 outcomes.Frontiers in immunology · 2024Article
- Bacterial Proteases as Potentially Exploitable Modulators of SARS-CoV-2 Infection: Logic from the Literature, Informatics, and Inspiration from the Dog.Biotech (Basel (Switzerland)) · 2023Article
- Plasminogen activator inhibitor 1 is not a major causative factor for exacerbation in a mouse model of SARS-CoV-2 infection.Scientific reports · 2023Article
- Urokinase-type plasminogen activator and plasminogen activator inhibitor-1 complex as a serum biomarker for COVID-19.Frontiers in immunology · 2023Article
- Lamin A to Z in normal aging.Aging · 2022Article
- The favorable impacts of silibinin polyphenols as adjunctive therapy in reducing the complications of COVID-19: A review of research evidence and underlying mechanisms.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2022Review
- Pharmacotherapy consideration of thrombolytic medications in COVID-19-associated ARDS.Journal of intensive care · 2022Review
- Hypoxia and Hypercoagulability in COVID-19: Chicken or the Egg?Anesthesiology · 2022Article
- Fibrinolytic Proteins and Factor XIII as Predictors of Thrombotic and Hemorrhagic Complications in Hospitalized COVID-19 Patients.Frontiers in cardiovascular medicine · 2022Article
- Biological effects of COVID-19 on lung cancer: Can we drive our decisions.Frontiers in oncology · 2022Review
- Clinical Management of COVID-19 in Cancer Patients with the STAT3 Inhibitor Silibinin.Pharmaceuticals (Basel, Switzerland) · 2021Article
- The impact of alterations in lamin A on genome integrity.Mutation research. Reviews in mutation researchReview
Corrections and comments
- Comment on
Authors and funding
1 author at 1 institution in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.